New Market - February 4, 2021
Elypta launches research service for glycosaminoglycan profiling
Elypta has announced the launch of the first standardized service for full spectrum glycosaminoglycan quantification for researchers. Elypta is also launching a sponsorship program to support more academic research in the field, prioritizing fundamental, pre-clinical, and clinical questions about how glycosaminoglycans relate to cancer. Glycosaminoglycan profiling Glycosaminoglycans (GAGs) are polysaccharides with relevance across a wide […]
New Market - January 19, 2021
Oasmia secures IP rights in Australia and Brazil
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea (paclitaxel micellar), which is being launched in […]
In a new job - September 7, 2020
Nanoform expands its global commercial team
Nanoform has appointed Eric Peter and Sergie Letser to drive the company’s business development in the US. The expansion to Nanoform’s commercial team will give the company a strengthened presence in the US market and enable a continued rate of rapid global growth, it states. Eric Peter Eric Peter will utilize his business development and […]
New Market - July 28, 2020
Rybelsus approved in Japan for the treatment of type 2 diabetes
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in Japan is based on results from the PIONEER clinical […]
New Market - April 2, 2020
LINK Medical Research opens London office
LINK Medical has announced the opening of its new UK office at MedCity, in London’s City region. The expansion to London will enable the company to bring significant value to UK-based biopharma and medtech companies by accelerating their product development, they state in their press release. The MedCity location was strategically chosen for its world-leading […]
New Market - March 30, 2020
AstraZeneca’s Imfinzi approved in the US for extensive small cell lung cancer
AstraZeneca’s Imfinzi has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing […]
